The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial
1992

Effects of Radiotherapy and Chemotherapy in Stage II Breast Cancer

Sample size: 200 publication Evidence: moderate

Author Information

Author(s): C. Blomqvist, K. Tiusanen, I. Elomaal, P. Rissanen, T. Hietanen, E. Heinonen, P. Grohn

Primary Institution: University of Helsinki

Hypothesis

Does the combination of radiotherapy, chemotherapy, and tamoxifen improve outcomes in stage II breast cancer?

Conclusion

Adjuvant chemotherapy improved relapse-free survival, but tamoxifen did not enhance overall survival.

Supporting Evidence

  • Chemotherapy improved relapse-free survival compared to radiotherapy alone.
  • Tamoxifen improved survival in estrogen receptor positive patients.
  • 32% of patients discontinued treatment due to gastrointestinal toxicity.

Takeaway

This study looked at how different treatments for breast cancer work together. It found that while chemotherapy helps prevent cancer from coming back, adding tamoxifen didn't help overall survival.

Methodology

Patients were randomized into four treatment groups: radiotherapy, chemotherapy, both, and both with tamoxifen.

Limitations

High toxicity led to treatment discontinuations and dose reductions in many patients.

Participant Demographics

Mean age was 52 years; 53% were estrogen receptor positive.

Statistical Information

P-Value

P = 0.004

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication